Treats insomnia characterized. ANDA 216041, held by Aurobindo Pharma Ltd. Doxepin Hydrochloride.
As of Nov 16, 2026, ANDA 216041 (Doxepin Hydrochloride), held by Aurobindo Pharma Ltd, was first approved by FDA on Jul 25, 2024, with 0 approved supplements and 0 published complete response letters.
Doxepin tablets is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 25, 2024 | Original application | Approved | None posted |
| Doxepin HydrochlorideEQ 3MG BASE · tablet;oral | Doxepin Hydrochloride | Rx |
| Doxepin HydrochlorideEQ 6MG BASE · tablet;oral | Doxepin Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters